Cambridge, MA-based Synlogic, the synthetic biology startup developing “smart bug” drugs called synthetic biotics, has named Bharatt Chowrira its president. Chowrira was formerly the chief operating officer of Auspex Pharmaceuticals, which Teva Pharmaceutical Industries bought for over $3 billion in March. He’ll work alongside CEO and former Pfizer executive Jose-Carlos Gutierrez Ramos, who joined Synlogic in May.
Separately, Synlogic also disclosed that it’s signed an R&D deal with an unspecified pharma company to develop drugs for certain forms of inflammatory bowel disease like Crohn’s disease and ulcerative colitis. The company has also identified two lead programs—prospective therapies for urea cycle disorder and phenylketonuria—that it’s advancing towards clinical trials.